表型
糖酵解
生物
代谢途径
转录组
计算生物学
胶质母细胞瘤
代谢组学
代谢网络
代谢活性
代谢稳定性
生物信息学
癌症研究
核糖核酸
分子成像
自噬
氨基酸
精密医学
新陈代谢
遗传学
危险分层
代谢调节
生物标志物
生物化学
焊剂(冶金)
作者
Elizabeth J. Li,Adam Kraya,Pedro Costa-Pinheiro,Joshua Scheuermann,Anthony J. Young,Erin K. Schubert,Mariam Aboian,R. K. Doot,Jeffrey B. Ware,Austin R. Pantel,Zev A. Binder,Phillip B. Storm,Adam C. Resnick,Nduka M. Amankulor,Donald M. O’Rourke,Arati Desai,MacLean P. Nasrallah,Steven Brem,Stephen Bagley,D. A. Mankoff
出处
期刊:Journal of nuclear medicine
[Society of Nuclear Medicine and Molecular Imaging]
日期:2026-03-19
卷期号:: jnumed.125.271476-jnumed.125.271476
标识
DOI:10.2967/jnumed.125.271476
摘要
Recurrent glioblastoma remains a clinical challenge because of metabolic heterogeneity and the difficulty in differentiating true progression from therapy-related changes. Methods: We conducted a prospective study with 30 patients, combining dynamic 18F-fluciclovine PET, perfusion MRI, and transcriptome profiling. Results: Kinetic PET parameters and MRI-derived blood volume measures correlated with overall survival. RNA sequencing revealed that high tracer uptake was associated with amino acid transport and autophagy pathways, whereas low uptake was linked to glycolysis signatures. Conclusion: In this cohort, molecular imaging metrics were closely connected to metabolic programs in glioblastoma, providing mechanistic insights into tumor biology in vivo. Beyond glioblastoma, this integrated imaging-omics approach may have potential applications in biomarker-driven patient stratification and targeted therapy in precision oncology.
科研通智能强力驱动
Strongly Powered by AbleSci AI